| Title: |
Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback home in children and adolescents with ADHD |
| Authors: |
Kaiser, Anna; Aggensteiner, Pascal M; Blasco Fontecilla, Hilario; Ros, Tomas; Acquaviva, Eric; Attal, Yohan; Banaschewski, Tobias; Baumeister, Sarah; Bousquet, Elisa; Bussalb, Aurore; Delhaye, Marie; Delorme, Richard; Drechsler, Renate; Goujon, Allison; Häge, Alexander; Mayaud, Louis; Mechler, Konstantin; Menache, Caroline; Revol, Olivier; Tagwerker, Friederike; Walitza, Susanne; Werling, Anna Maria; Bioulac, Stéphanie; Purper-Ouakil, Diane; Brandeis, Daniel |
| Source: |
ISSN: 1664-0640 ; Frontiers in psychiatry, vol. 14 (2024) 1331004. |
| Publication Year: |
2024 |
| Collection: |
Université de Genève: Archive ouverte UNIGE |
| Subject Terms: |
info:eu-repo/classification/ddc/616.8; ADHD; Executive functions; Methylphenidate; Neurocognitive functioning; Neurofeedback; Predictive marker; Treatment marker |
| Description: |
Introduction: Earlier studies exploring the value of executive functioning (EF) indices for assessing treatment effectiveness and predicting treatment response in attention-deficit/hyperactivity disorder (ADHD) mainly focused on pharmacological treatment options and revealed rather heterogeneous results. Envisioning the long-term goal of personalized treatment selection and intervention planning, this study comparing methylphenidate treatment (MPH) and a home-based neurofeedback intervention (NF@Home) aimed to expand previous findings by assessing objective as well as subjectively reported EF indices and by analyzing their value as treatment and predictive markers. Methods: Children and adolescents ( n = 146 in the per protocol sample) aged 7-13 years with a formal diagnosis of an inattentive or combined presentation of ADHD were examined. We explored the EF performance profile using the Conners Continuous Performance Task (CPT) and the BRIEF self-report questionnaire within our prospective, multicenter, randomized, reference drug-controlled NEWROFEED study with sites in five European countries (France, Spain, Switzerland, Germany, and Belgium). As primary outcome for treatment response, the clinician-rated ADHD Rating Scale-IV was used. Patients participating in this non-inferiority trial were randomized to either NF@home (34-40 sessions of TBR or SMR NF depending on the pre-assessed individual alpha peak frequency) or MPH treatment (ratio: 3:2). Within a mixed-effects model framework, analyses of change were calculated to explore the predictive value of neurocognitive indices for ADHD symptom-related treatment response. Results: For a variety of neurocognitive indices, we found a significant pre-post change during treatment, mainly in the MPH group. However, the results of the current study reveal a rather limited prognostic value of neurocognitive indices for treatment response to either NF@Home or MPH treatment. Some significant effects emerged for parent-ratings only. Discussion: Current findings indicate a ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/38312916; info:eu-repo/grantAgreement/EC/H2020/684809/EU/Personalized medical device for the diagnosis and treatment of ADHD based on EEG biomarkers and Neurofeedback Training/NEWROFEED; unige:184174 |
| Availability: |
https://archive-ouverte.unige.ch/unige:184174 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.3CDCC1E6 |
| Database: |
BASE |